Cambridge Investment Research Advisors’s Aclaris Therapeutics ACRS Stock Holding History

Cambridge Investment Research Advisors’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$222K	Hold	41,873	–	–	﹤0.01%	3727
2026 Q1	$157K	Hold	41,873	–	–	﹤0.01%	3727
2025 Q4	$126K	Hold	41,873	–	–	﹤0.01%	3670
2025 Q3	$80K	Hold	41,873	–	–	﹤0.01%	3612
2025 Q2	$59K	Hold	41,873	–	–	﹤0.01%	3522
2025 Q1	$64K	Hold	41,873	–	–	﹤0.01%	3390
2024 Q4	$104K	Hold	41,873	–	–	﹤0.01%	3324
2024 Q3	$48K	Hold	41,873	–	–	﹤0.01%	3334
2024 Q2	$46K	Hold	41,873	–	–	﹤0.01%	3222
2024 Q1	$52K	Hold	41,873	–	–	﹤0.01%	3208
2023 Q4	$44K	Buy	41,873 +26,535	+173%	+$81K	﹤0.01%	3107
2023 Q3	$105K	Hold	15,338	–	–	﹤0.01%	2956
2023 Q2	$159K	Hold	15,338	–	–	﹤0.01%	2936
2023 Q1	$124K	Hold	15,338	–	–	﹤0.01%	2927
2022 Q4	$242K	Sell	15,338 -200	-1%	-$3.22K	﹤0.01%	2600
2022 Q3	$245K	Buy	15,538 +200	+1%	+$3.15K	﹤0.01%	2535
2022 Q2	$214K	Hold	15,338	–	–	﹤0.01%	2677
2022 Q1	$264K	Hold	15,338	–	–	﹤0.01%	2650
2021 Q4	$223K	Hold	15,338	–	–	﹤0.01%	2782
2021 Q3	$276K	Buy	15,338 +638	+4%	+$10.2K	﹤0.01%	2529
2021 Q2	$258K	Hold	14,700	–	–	﹤0.01%	2586
2021 Q1	$370K	Sell	14,700 -30,073	-67%	-$588K	﹤0.01%	2131
2020 Q4	$290K	Buy	44,773 +73	+0.2%	+$308	﹤0.01%	2171
2020 Q3	$115K	Hold	44,700	–	–	﹤0.01%	2373
2020 Q2	$72K	Hold	44,700	–	–	﹤0.01%	2351
2020 Q1	$46K	Hold	44,700	–	–	﹤0.01%	2185
2019 Q4	$84K	Hold	44,700	–	–	﹤0.01%	2327
2019 Q3	$48K	Buy	+44,700	New	+$63.4K	﹤0.01%	2283

Other funds holding ACRS

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Cambridge Investment Research Advisors's ACRS Position: Q2 2026 in Review

Cambridge Investment Research Advisors held its Aclaris Therapeutics (ACRS) position steady in Q2 2026 at 41,873 shares worth $222K. The position accounts for ﹤0.01% of the portfolio, ranked #3727.

Cambridge Investment Research Advisors first reported a position in ACRS in Q3 2019 and has held it in 28 quarters since. The position peaked at $370K in Q1 2021. 148 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

Cambridge Investment Research Advisors held 41,873 shares of Aclaris Therapeutics worth $222K as of Q2 2026.
Cambridge Investment Research Advisors left its Aclaris Therapeutics share count unchanged in Q2 2026.
Aclaris Therapeutics made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #3727 holding.
Cambridge Investment Research Advisors first reported a position in Aclaris Therapeutics in Q3 2019 and has held it in 28 quarters since.
Cambridge Investment Research Advisors's Aclaris Therapeutics position peaked at $370K in Q1 2021.
148 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.